Non-public Issue of A Shares and Connected Tran...
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong
Limited take no responsibility for the contents of thisannouncement, make no
representation as to its accuracy or completeness and expressly disclaim any
liability whatsoever for any loss howsoever arising from or in reliance upon
the whole or any part of the contents of thisannouncement.
DATANG INTERNATIONAL POWER GENERATION CO., LTD.
(a sino-foreign joint stock limited company incorporated in the People's
Republic of China)
(Stock Code: 991)
ANNOUNCEMENT
NON-PUBLIC ISSUE OF A SHARES
AND
CONNECTED TRANSACTION
Non-public Issue of A Shares
The Board is pleased to announce that the proposal relating to the issue of A
Shares by way of non-public issue was approved by the Board on 25 May 2010,
pursuant to which the Company will issue up to a maximum of 1,000,000,000 A
Shares to not more than 10 qualified investors at the issue price of not less
than RMB6.81 (approximately equivalent to HK$7.74) per A Share.
The Subscription Agreement
The Board is pleased to announce that on 25 May 2010, the Company and CDC
entered into the Subscription Agreement which will be effective subject to
certain conditions. Pursuant to the Subscription Agreement, CDC proposed to
subscribe in cash at the price of not less than RMB6.81 per Share for 10% (i.e.
approximately 100,000,000 A Shares) of the ultimate total number of A Shares to
be issued by way of non-public issue. The total consideration will be
approximately RMB681 million. The subscription price to be offered by CDC will
be the same as the subscription price payable by other investors in the current
non-public issue of A Shares.
Connected Transaction
As at the date of the announcement, CDC and its subsidiaries hold a total of
approximately 35.08% of the issued share capital of the Company. Accordingly,
CDC is a Connected Person of the Company under Chapter 14 of the Listing Rules
and the entering into of the Subscription Agreement constitutes a connected
transaction of the Company under Chapter 14A of the Listing Rules.
As each of the applicable percentage ratios (as defined in Rule 14.07 of the
Listing Rules) of the Subscription Agreement is more than 0.1% but less than
2.5%, the transaction contemplated under the Subscription Agreement is only
subject to the reporting and announcement requirements under Rules 14A.45 to
14A.47 of the Listing Rules and does not require the approval by the
independent Shareholders of the Company under Chapter 14A of the Listing Rules.
I. NON-PUBLIC ISSUE OF A SHARES
The proposal relating to the issue of A Shares by way of non-public issue was
approved by the Board on 25 May 2010, pursuant to which the Company will issue
up to a maximum of 1,000,000,000 A Shares by way of non-public issue to not
more than 10 qualified investors.
1. The proposal of non-public issuance of A Shares
(1) Type of Shares to be issued and par value
The type of shares to be currently issued is domestic listed RMB-denominated
ordinary Shares (A Shares) with a par value of RMB1.00 per Share.
(2) Method and time of issue
All Shares under the current issue shall be issued to specific targets by means
of non-public issue. Shares shall be issued to specific targets at any suitable
time chosen by the Company within six months upon the approval by the CSRC.
(3) Target subscribers and subscription method
The target subscribers under the current non-public issue shall not be more
than ten specific investors, including CDC. Except for CDC, the Board and the
lead underwriter shall determine other specific investors by way of price
consultation according to the relevant provisions of the CSRC after obtaining
the approval document from the CSRC. All target subscribers shall subscribe for
the Shares under the current issue by way of cash.
(4) Number of shares to be issued
The number of A Shares to be issued in the current non-public issue shall not
be more than one billion Shares (inclusive of one billion Shares). In the event
of any trading of Shares on ex-right or ex-dividend basis from the date of the
announcement on the resolutions of the Board, i.e., 26 May 2010, to the issue
date, the number of A Shares to be issued under the current non-public issue
shall be adjusted accordingly.
(5) Issue price and method of pricing
The issue price of the current non-public issue of A Shares shall not be lower
than 90% of the average trading prices of the Company's A Shares (i.e., RMB6.81
per Share) for the 20 trading days immediately preceding the date of the
announcement on the resolutions of the Board i.e., 26 May 2010. The final issue
price shall be determined on a best available price basis with reference to the
subscription quotations of the target subscribers after obtaining the approval
documents for the issue. CDC shall not participate in the process of the market
price consultation regarding the pricing of the current issue, but undertakes
that it will accept the result of the price consultation and shall subscribe
for the Shares at the same price as other investors.
(6) Arrangement for the lock-up period
The A Shares to be subscribed by CDC under the current non-public issue shall
not be transferred within 36 months commencing from the date of the completion
of the issue. The A shares to be subscribed by other target subscribers under
the current non-public offering shall not be transferred within 12 months
commencing from the date of the completion of the issue.
(7) Place of listing
The Shares under the current issue shall be listed and traded on the Shanghai
Stock Exchange after expiry of the lock-up period.
2. Conditions of the non-public issue of A Shares
Completion of the non-public issue of A Shares is subject to, among others, (i)
the approval by the Shareholders at the AGM on the authorisation to the Board
to deal with the relevant matters relating to the non-public issue of A Shares
at the Board's discretion; (ii) the approval by the Shareholders at the AGM on
the relevant resolutions relating to the proposal on the non-public issue of A
Shares and other relevant resolutions relating to the non-public issue of A
Shares, including the proposed use of the fundraising proceeds; and (iii) the
obtaining of all necessary consents, approvals and authorisation from relevant
government authorities (including but not limited to the approval by the CSRC).
As CDC is a party to the Subscription Agreement and will participate in the
current non-public issue of A Shares, CDC shall abstain from voting at the AGM
to approve the "Resolution for Non-public Issue of A Shares".
3. Use of fundraising proceeds
It is estimated that the proposed net proceeds from the current non-public
issue of A Shares (inclusive of the subscription of A Shares to be made by CDC
under the Subscription Agreement) shall not exceed RMB8 billion and the Company
plans to invest such proceeds in the following projects:
No. Project to be funded by the fundraising Total investment Proceeds to be
proceeds of the project invested
(RMB billion) (RMB billion)
1 Inner Mongolia Datang International Keqi 25.710 2.000
Coal-based Natural Gas Project (with
daily production of 12 million N cubic
metres)
2 Liaoning Datang International Fuxin 24.570 1.814
Coal-based Natural Gas Project (with
daily production of 12 million N cubic
metres)
3 Phase 1 at the Fujian Ningde Nuclear 49.342 1.223
Power Project
4 Chongqing Wujiang Yinpan Hydropower 8.045 0.600
Station
5 Liaoning Datang International Fuxin 0.483 0.097
Qianchatai Windpower Project
6 Liaoning Datang International Fuxin 0.480 0.096
Houchatai Windpower Project
7 Inner Mongolia Datang International 0.448 0.094
Chayouhouqi Hongmu Windpower Mill Phase
2 Project
8 Phase 1 of East Unit 2 open-cut coal 2.965 0.376
mine project located in Shengli Coal
Mine
9 Repayment of bank loans - 1.700
Total - 8.000
In the event that the Company have already carried out the investment in
certain relevant projects by using bank loans and internal resources prior to
obtaining the proceeds, the proceeds from the fundraising shall be used for
repaying the relevant bank loans and replenishing the Company's working capital
after obtaining the proceeds. In the event that the actual net proceeds from
the fundraising under the current issue are not sufficient for fulfilling the
capital required for the projects, the insufficient portion will be satisfied
by the Company's internally generated funds. In the event that the actual net
proceeds under the current issue exceed the capitals required for the projects,
the excess portion shall be used to replenish the Company's working capital.
The proposed non-public issue of A Shares is expected to be made under a
general mandate to be granted to the Board in the AGM in accordance with Rules
13.36(2)(b) and 19A.38 of the Listing Rules (for details of the general
mandate, please refer to notice of AGM dated 26 April 2010).
II. THE SUBSCRIPTION AGREEMENT
The Company and CDC entered into the Subscription Agreement on 25 May 2010
which will be effective subject to certain conditions. Pursuant to the
Subscription Agreement, CDC proposed to subscribe in cash at the price of not
less than RMB6.81 per Share for 10% (i.e. approximately 100,000,000 A Shares)
of the ultimate total number of A Shares with nominal value of RMB1.00 per
Share to be issued by way of non-public issue. The total consideration will be
approximately RMB681 million. The subscription price to be offered by CDC will
be the same as the subscription price for other investors in the current
non-public issue of A Shares.
Date
25 May 2010
Parties:
1. the Company; and
2. CDC
Principal Terms of the Subscription Agreement
1. The Company proposed to issue not more than 1,000,000,000 A Shares (ordinary
shares with nominal value of RMB1.00 per Share) by way of non-public issue to
not more than 10 target investors, including CDC.
2. Subscription target and size: CDC proposed to subscribe in cash for 10% of
the ultimate total number of A Shares to be issued, i.e. approximately
100,000,000 A Shares. In the event of any trading of Shares on ex-right or
ex-dividend basis from the date of the announcement on the resolutions of the
Board, i.e., 26 May 2010, to the date of the issue, the subscription price of
the A Shares to be subscribed by CDC under the current non-public issue shall
be adjusted accordingly.
3. Subscription price and pricing method: The subscription price to be paid by
CDC for the subscription of each of the A Shares under the current non-public
issue will be equal to the issue price of each of the A Shares under the
current non-public issue (i.e. the subscription price payable by other target
investors), i.e., not less than RMB6.81 (approximately equivalent to HK$7.74)
per A Share, which shall not be lower than 90% of the average trading prices of
the Company's A Shares (i.e., RMB7.57 per share) for the 20 trading days
immediately preceding the date of the announcement on the resolutions of the
Board (i.e. 26 May 2010). The final issue price shall be determined on a best
available price basis with reference to the subscription quotations of the
target subscribers after obtaining the approval documents for the issue. CDC
will not participate in the price quoting process for this issuance. The
minimum issue price for the non-public issue of the A Shares will be adjusted
accordingly if any ex-right or ex-dividend events in respect of the shares of
the Company occur during the period from the date of the announcement on the
resolutions of the Board (i.e., 26 May 2010) to the date of the issue.
4. Lock-up period: The Shares to be subscribed by CDC under the non-public
issue shall not be transferred within thirty six (36) months from the
completion date of the issue.
5. Subscription method: CDC will subscribe for the Shares by way of cash.
6. Payment method of subscription amount: As at the date of the settlement, CDC
will transfer the subscription amount to the account for the current non-public
issue of A Shares specifically opened by the sponsor of the current non-public
issue of A Shares.
7. Conditions: The Subscription Agreement is conditional upon, including but
not limited to, the completion of the following conditions:
1. The approval of the non-public issuance of A Shares by the Shareholders at
the general meeting of the Company.
2. The approval of the non-public issue of A Shares given by the State-owned
Assets Supervision and Administration Commission of the State Council.
3. The approval of the non-public issue of A Shares given by the Office of
General Manager of the CDC.
4. The approval of the current non-public issue of A Shares by the CSRC.
Information on the Group and CDC
The Group is principally engaged in the construction and operation of power
plants, the sale of electricity and thermal power, the repair and maintenance
of power equipment and power related technical services, with its main service
areas being in the PRC.
CDC is a state-owned enterprise. Its scope of operations includes the
development, investment, construction, operation and management of power
energy; organisation of power (thermal) production and sales; as well as power
technology development and consultation.
Connected Transaction
The A Shares to be subscribed by CDC under the current non-public issue of A
Shares is expected to be made under a general mandate to be granted to the
Board in the AGM in accordance with Rules 13.36(2)(b) and 19A.38 of the Listing
Rules (For details of the general mandate, please refer to notice of AGM dated
26 April 2010).
As at the date of the announcement, CDC and its subsidiaries hold a total of
approximately 35.08% of the issued share capital of the Company. Accordingly,
CDC is a Connected Person of the Company under Chapter 14 of the Listing Rules
and the entering of the Subscription Agreement constitutes a connected
transaction of the Company under Chapter 14A of the Listing Rules.
As each of the applicable percentage ratios (as defined in Rule 14.07 of the
Listing Rules) of the Subscription Agreement is more than 0.1% but less than
2.5%, the transaction contemplated under the Subscription Agreement is only
subject to the reporting and announcement requirements under Rules 14A.45 to
14A.47 of the Listing Rules and does not require the approval by the
independent Shareholders of the Company under Chapter 14A of the Listing Rules.
Reasons for and Benefits of the Non-Public Issue of A Shares and the
Subscription Agreement
In recent years, under the strategic direction of "Focus in Power Generation,
Pursue Synergistic Diversifications", the Company has been increasing
investments in projects such as coal-fired power, hydropower, wind power and
nuclear power as well as power-related upstream and downstream businesses such
as coal mining, coal chemical and railway projects in order to meet the
Company's increasingly growing business needs. The non-public issue of A Shares
will leverage the resource allocation function of the capital market, capture
favourable market opportunities, enrich the Company's capital funds, expand the
Company's production capacity and core competitiveness, and improve the
Company's capital structure.
The entering into of the Subscription Agreement also represents CDC's strong
confidence in, and support to, the future developments of the Company.
The Directors, including independent non-executive Directors, are of the view
that the terms of the CDC Subscription Agreement are normal commercial terms,
fair and reasonable and in the interest of the Company and its Shareholders as
a whole.
III. FUND RAISING ACTIVITIES IN THE PAST 12 MONTHS
Save for the capital raising activities mentioned below, there has not been any
other capital raising activity of the Company in the 12 months preceding the
date of this announcement:
Date of Event Approximate Intended use Actual use of
announcement net proceeds of proceeds proceeds as at the
date of this
announcement
24 March, 2010 530,000,000 RMB3,248,246,600 The As at the date of
A Shares fundraising the announcement,
were issued proceeds were the fundraising
to specific primarily proceeds have been
targets by used in the used up in
way of construction accordance with
non-public of power the fundraising
issue generation proceeds usage
projects. plan. For details,
please refer to
the "Previous
Fundraising
Proceeds Usage
Report and the
Verification
Report" published
on the websites of
the Shanghai Stock
Exchange (
www.sse.com.cn)
and the Stock
Exchange
(www.hkex.com.hk)
on 26 May 2010.
IV. THE STRUCTURE OF THE SHAREHOLDING OF THE COMPANY
The shareholding structures of the Company immediately before and after the
current non-public issue of 1,000,000,000 A Shares will be as follows:
Immediately before the completion of Immediately after the completion of
the non-public issue of A Shares of the non-public issue of A Shares of
the Company the Company
Name of Number of Percentage Percentage Number of Percentage Percentage
Shareholder Shares held of total of total Shares held of total of total
issued A issued issued A issued
Shares of share Shares of share
the capital of the capital of
Company(%) the Company(%) the
Company(%) Company(%)
CDC A Shares: 44.02 32.17 A Shares: 40.62 30.50
3,959,241,160 4,059,241,160
H Shares: Not 2.91 H Shares: Not 2.69
358,680,000 Applicable 358,680,000 Applicable
Other 5,035,118,840 55.98 40.90 5,035,118,840 50.38 37.83
Shareholders
holding A
Shares
Other 2,956,997,578 Not 24.02 2,956,997,578 Not 22.22
Shareholders Applicable Applicable
holding H
Shares
Other target Not Applicable Not Not 900,000,000 9.00 6.76
investors Applicable Applicable
(excluding
CDC)
Total: 12,310,037,578 100 100 13,310,037,578 100 100
DEFINITIONS
In this announcement, unless the context otherwise requires, the following
expressions have the following meanings:
"AGM" the 2009 annual general meeting to be convened by
the Company at the function room of 5/F,
Intercontinental Hotel, No. 11 Financial Street,
Xicheng District, Beijing, the PRC on 11 June 2010
(Friday) at 9:00 a.m.
"A Share(s)" the domestic ordinary share(s) of the Company with
a nominal value of RMB1.00 per share and are listed
on the Shanghai Stock Exchange
"Board" the board of Directors
"CDC" China Datang Corporation, a State-owned enterprise
established under the laws of the PRC and is a
controlling shareholder of the Company pursuant to
the Listing Rules. CDC and its subsidiaries own
approximately 35.08% of the issued share capital of
the Company as at the date of this announcement
"Company" Datang International Power Generation Co., Ltd., a
sino-foreign joint stock limited company
incorporated in the PRC on 13 December 1994, whose
H Shares are listed on the Stock Exchange and the
London Stock Exchange and whose A Shares are listed
on the Shanghai Stock Exchange
"Connected Person" has the meaning ascribed to it under the Listing
Rules
"CSRC" the China Securities Regulatory Commission
"Director(s)" the director(s) of the Company
"Domestic Shares" the ordinary shares issued by the Company with a
nominal value of RMB1.00 each, which are subscribed
for or credited as paid up in Renminbi
"Group" the Company and its subsidiaries
"HK$" Hong Kong dollar(s), the lawful currency of Hong
Kong
"Hong Kong" the Hong Kong Special Administrative Region of the
PRC
"H Share(s)" the overseas listed foreign shares of the Company
with a nominal value of RMB1.00 each, which are
listed on the Stock Exchange and the London Stock
Exchange
"Listing Rules" The Rules Governing the Listing of Securities on
the Stock Exchange
"PRC" the People's Republic of China
"RMB" Renminbi, the lawful currency of the PRC
"Shares" the ordinary shares of the Company with a nominal
value of RMB1.00 each, comprising domestic Shares
and H Shares
"Shareholder(s)" the holder(s) of the Share(s)
"Stock Exchange" The Stock Exchange of Hong Kong Limited
"Subscription the subscription agreement dated 25 May 2010
Agreement" entered into between the Company and CDC relating
to the subscription by CDC of A Shares to be issued
by way of non-public issue by the Company
"%" per cent
Note: Unless otherwise specified and for reference only, the conversion of Hong
Kong dollars into Renminbi is based on the exchange rate of HK$1= RMB0.877 in
this announcement
By Order of the Board
Zhou Gang
Secretary to the Board
Beijing, the PRC, 25 May 2010
As at the date of this announcement, the Directors of the Company are:
Zhai Ruoyu, Hu Shengmu, Cao Jingshan, Fang Qinghai, Zhou Gang, Liu Haixia, Guan
Tiangang, Su Tiegang, Ye Yonghui, Li Gengsheng, Xie Songlin*, Liu Chaoan*, Yu
Changchun*, Xia Qing* and Li Hengyuan*.
*Independent non-executive Directors